11/11
11:15 pm
mnkd
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/11
11:15 pm
mnkd
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/8
02:48 am
mnkd
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
11/7
11:28 pm
mnkd
MannKind (MNKD) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
MannKind (MNKD) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/7
04:18 pm
mnkd
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update [Yahoo! Finance]
11/7
04:02 pm
mnkd
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Low
Report
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
11/6
07:21 am
mnkd
MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
Low
Report
MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
11/5
04:15 pm
mnkd
MannKind to Present at 2024 UBS Healthcare Conference
Low
Report
MannKind to Present at 2024 UBS Healthcare Conference
11/4
06:12 am
mnkd
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases [Yahoo! Finance]
Medium
Report
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases [Yahoo! Finance]
11/4
06:05 am
mnkd
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
Low
Report
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
11/1
10:55 am
mnkd
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? [Yahoo! Finance]
Low
Report
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? [Yahoo! Finance]
10/31
04:05 pm
mnkd
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
Low
Report
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
10/7
02:06 pm
mnkd
Why MannKind (MNKD) Could Beat Earnings Estimates Again [Yahoo! Finance]
Low
Report
Why MannKind (MNKD) Could Beat Earnings Estimates Again [Yahoo! Finance]
10/3
08:08 am
mnkd
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion [Seeking Alpha]
Low
Report
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion [Seeking Alpha]
9/30
06:00 am
mnkd
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
Low
Report
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
9/25
04:13 am
mnkd
Developments in Nontuberculous Mycobacterial Infections Pipeline for 2024 [Yahoo! Finance]
Low
Report
Developments in Nontuberculous Mycobacterial Infections Pipeline for 2024 [Yahoo! Finance]
9/18
06:21 am
mnkd
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease [Yahoo! Finance]
Low
Report
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease [Yahoo! Finance]
9/18
06:15 am
mnkd
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
Low
Report
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
9/10
04:30 pm
mnkd
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
Low
Report
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
9/10
05:56 am
mnkd
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/9
09:01 am
mnkd
MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
Low
Report
MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
8/28
09:18 am
mnkd
MannKind Co. (NASDAQ: MNKD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $10.00 to $12.00. They now have an "outperform" rating on the stock.
Medium
Report
MannKind Co. (NASDAQ: MNKD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $10.00 to $12.00. They now have an "outperform" rating on the stock.
8/27
04:33 pm
mnkd
MannKind to Present at Upcoming Conferences [Yahoo! Finance]
Medium
Report
MannKind to Present at Upcoming Conferences [Yahoo! Finance]
8/27
04:30 pm
mnkd
MannKind to Present at Upcoming Conferences
Medium
Report
MannKind to Present at Upcoming Conferences